Skip to main content
. 2018 Feb 1;11(4):345–351. doi: 10.1111/cts.12540

Figure 1.

Figure 1

Modeling and simulation in drug development. BLA: Biologics License Applications; EOP2: End of phase II study; IND: Investigational New Drug; M&S: Modeling and Simulation; NDA: New Drug Application; PBPK: Physiologically‐based Pharmacokinetics; PK/PD: Pharmacokinetics/Pharmacodynamics; PopPK: Population Pharmacokinetics.